MWNA
PRNB

Marshall Wace North America’s Principia Biopharma Inc. Common Stock PRNB Stock Holding History

Marshall Wace North America’s Portfolio PRNB Stock Details PRNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-17,717
Closed -$603K – 1830
2019
Q1 		$603K Buy
17,717
+2,266
+15% +$72.1K ﹤0.01% 759
2018
Q4 		$423K Buy
15,451
+1,651
+12% +$42.5K ﹤0.01% 815
2018
Q3 		$403K Buy
+13,800
New +$389K ﹤0.01% 737

Other funds holding PRNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace North America's PRNB Position: Q2 2019 in Review

Marshall Wace North America sold out of Principia Biopharma Inc. Common Stock (PRNB) in Q2 2019, closing a stake of 17,717 shares — an estimated $603K sold.

Marshall Wace North America first reported a position in PRNB in Q3 2018 and held it in 3 quarters. The position peaked at $603K in Q1 2019. 74 funds tracked by Wall St. Rank hold PRNB as of Q2 2019.

  • Marshall Wace North America reported no remaining Principia Biopharma Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Marshall Wace North America sold 17,717 Principia Biopharma Inc. Common Stock shares in Q2 2019, an estimated $603K.
  • Marshall Wace North America first reported a position in Principia Biopharma Inc. Common Stock in Q3 2018 and held it in 3 quarters.
  • Marshall Wace North America's Principia Biopharma Inc. Common Stock position peaked at $603K in Q1 2019.
  • 74 funds tracked by Wall St. Rank held Principia Biopharma Inc. Common Stock as of Q2 2019.

Based on Marshall Wace North America's 13F filing for Q2 2019, filed 14 Aug 2019.